Search

A report presented Thursday at the Clinical Trials in Alzheimer's Disease meeting in Madrid stated that researchers found that when a transcranial magnetic stimulation, or TMS, device was aimed at [...]

For the first time, scientists in China reprogrammed a woman's fat cells to turn them into insulin-making pancreatic cells that reversed her type 1 diabetes. The feat adds to a [...]

Vaccinex provided an update on new clinical findings from its SIGNAL-AD Phase 1b/2 trial of pepinemab antibody in Alzheimer's disease. Vaccinex recently announced results of the phase 1b/2 study of [...]

Intensity Therapeutics and The Swiss Group for Clinical Cancer Research SAKK, a decentralized academic research institute that has been conducting clinical trials of cancer treatments in all major Swiss hospitals [...]

Acumen Pharmaceuticals presented updated data on a validated research-use plasma pTau217 assay to screen potential participants in the ongoing Phase 2 ALTITUDE-AD clinical trial of sabirnetug, at the 17th Annual [...]

Psyence Biomedical announced the closing of its previously announced acquisition of Psyence Group's 11.13% stake in privately held PsyLabs. PsyLabs is focused on the cultivation and production of psychedelic active [...]

Cardiff Oncology announced the publication of data from its Phase 2 trial evaluating onvansertib in combination with Folfiri and bevacizumab for the second-line treatment of KRAS mutant metastatic colorectal cancer, [...]

Eisai Co (ESAIY) and Biogen Inc. (BIIB) announced that the latest findings for lecanemab-irmb, an anti-amyloid beta protofibril* antibody for the treatment of early Alzheimer's disease, were presented at the [...]

Inventiva announced the recommendation from the fifth scheduled meeting of the Data Monitoring Committee, or DMC, to continue the NATiV3 Phase 3 clinical trial evaluating lanifibranor in patients with MASH [...]

Spectral AI announced that the final group of burn center patients in the Company's U.S. Burn Pivotal Study have successfully completed their clinical visits. 'The completion of this aspect of [...]

Nexalin Technology announced publication of a landmark study titled, 'Altered Neuronal Activity Patterns of the Prefrontal Cortex in Alzheimer's Disease After Transcranial Alternating Current Stimulation, tACS,: A Resting-State Functional Magnetic [...]

Johnson & Johnson announced results from the Phase 3 GRAVITI study of Tremfya - guselkumab -, the first and only IL-23 inhibitor, demonstrating 'robust' results in subcutaneous induction and maintenance [...]

Travere Therapeutics presented new data further demonstrating the clinical benefit of FILSPARI in IgA nephropathy and reinforcing its potential in focal segmental glomerulosclerosis at the American Society of Nephrology Kidney [...]

Revolution Medicines announced preliminary safety and antitumor data for RMC-9805, its RAS G12D-selective inhibitor, in patients with previously treated pancreatic ductal adenocarcinoma, or PDAC. These initial results were presented during [...]

NeuroSense announced findings from its PARADIGM clinical trial of PrimeC. These results illuminate a new frontier in the treatment of ALS - Amyotrophic Lateral Sclerosis -, a disease long considered [...]

BioCryst Pharmaceuticals announced new real-world comparative research on the use of oral, once-daily ORLADEYO that found high rates of adherence and persistence for ORLADEYO, similar to the rates observed with [...]

Zai Lab presented data from the ongoing global Phase 1a/1b study of ZL-1310, a next-generation antibody-drug conjugate, or ADC, at the EORTC-NCI-AACR, or ENA, Symposium 2024 in Barcelona, Spain, as [...]

At September 30, 2024, Viking held cash, cash equivalents and short-term investments of $930 M vs. $362M as of December 31, 2023. 'The first three quarters of 2024 have been [...]

Alto Neuroscience 'announced that the Phase 2b study of ALTO-100 in patients with major depressive disorder did not meet its primary endpoint, assessed by a change from baseline in Montgomery-Asberg [...]

Gyre Therapeutics announced that the last patient in Gyre Pharmaceuticals' pivotal Phase 3 trial in the People's Republic of China or PRC evaluating F351 hydronidone for Chronic Hepatitis B CHB [...]

Nexalin Technology announced plans to commence a new clinical trial in collaboration with the University of California, San Diego. Dr Ming Xiong Huang, the UCSD principal investigator, will utilize his [...]

Quoin Pharmaceuticals announces the further expansion of its on-going Netherton Syndrome, NS, clinical studies to include two additional international sites in the United Kingdom, UK. These sites, Great Ormond Street [...]

Ocugen announced that the Data and Safety Monitoring Board, DSMB, for the OCU410ST GARDian clinical trial recently convened and approved enrollment for the second phase of the Phase 1/2 clinical [...]

Revolution Medicines announced that the first patient has been dosed in RASolute 302, a Phase 3 registrational study of RMC-6236, a RAS multi-selective inhibitor, in patients with previously treated, metastatic [...]

Regeneron announced three-year data for EYLEA HD Injection 8 mg from an extension study of the Phase 3 PHOTON trial in patients with diabetic macular edema, or DME. At three [...]

Defective mitochondria may disrupt the gut microbiome, driving the development of Crohn's disease, new research in mice suggests. If these findings hold true in humans, they could ultimately lead to [...]

Aura Biosciences announced early data from an ongoing Phase 1 clinical trial of bel-sar in patients with NMIBC. To date, the trial includes 13 patients, with the primary endpoints of [...]

Nektar Therapeutics announced the publication of the first clinical data from a Phase 1 study evaluating NKTR-255 in combination with an autologous bispecific chimeric antigen receptor (CAR)-T cell therapy targeting [...]

Acadia Pharmaceuticals announced that Health Canada has granted marketing authorization of DAYBUE for the treatment of Rett syndrome in adult and pediatric patients two years of age and older under [...]

Arbutus Biopharma announced that clinical data with imdusiran, an RNAi therapeutic, will be highlighted in four poster presentations at the American Association for the Study of Liver Diseases - The [...]

Annovis Bio announced the 'successful' outcome of the End-of-Phase 2 meeting with the U.S. Food and Drug Administration on October 10, 2024. During the meeting, the FDA granted clearance to [...]

NeuroSense Therapeutics announced it has initiated the regulatory process to seek early commercialization approval for PrimeC under Health Canada's Notice of Compliance with Conditions policy. This submission is based on [...]

BullFrog AI Holdings announced the publication of new research in the peer-reviewed journal Cell Reports supporting the potential of BullFrog AI's drug candidate, BF-114, in treating a range of liver [...]

Myriad Genetics announced a series of ongoing research collaborations to study the use of molecular residual disease, or MRD, testing in breast cancer using Myriad's Precise MRD test. A study [...]

Oncocyte announced the peer-reviewed publication of positive data related to its proprietary gene expression test, DetermaIO. The NeoTRIP Phase 2 clinical trial randomized patients with triple-negative breast cancer, TNBC, to [...]

Vincerx Pharma announced two complete responses in the ongoing first-in-human, Phase 1 dose-escalation study of VIP943, the company's next-generation antibody-drug conjugate, or ADC, being evaluated in relapsed/refractory acute myeloid leukemia, [...]

Scholar Rock announced topline results from the Phase 3 SAPPHIRE clinical trial evaluating the efficacy and safety of apitegromab, an investigational muscle-targeted therapy, in patients with SMA. The study achieved [...]

Monopar Therapeutics announced that the Phase 1a clinical trial for its novel therapeutic radiopharmaceutical MNPR-101-Lu is now active and recruiting patients with advanced cancers. The Phase 1a trial is an [...]

CytoMed Therapeutics has obtained full approval for its first-in-human Phase I clinical trial using its patented allogeneic chimeric antigen receptor T cell against several blood and solid tumors in collaboration [...]

Biodexa Pharmaceuticals announces an update in respect of its open label Phase 1 study of MTX110 in recurrent glioblastoma. In October 2023, the Company announced completed recruitment of four patients [...]

Following discussion with the US Naval Medical Research Command, Immuron can announce that the NMRC has completed the interim analysis for the clinical evaluation of a new oral therapeutic targeting [...]

Arcus Biosciences (RCUS) announced a clinical trial collaboration agreement with AstraZeneca (AZN) to evaluate casdatifan, Arcus's investigational HIF-2a inhibitor, in combination with volrustomig, AstraZeneca's investigational PD-1/CTLA-4 bispecific antibody, in patients [...]

aTyr Pharma announced the publication of a post hoc analysis of the Phase 1b/2a clinical trial of its lead therapeutic candidate, efzofitimod, in patients with pulmonary sarcoidosis, a major form [...]

BriaCell Therapeutics reports dramatic anti-tumor response including complete resolution of temporal lobe breast cancer metastasis in a patient treated in the Phase 2 study of BriaCell's Bria-IMT plus an immune [...]

Silexion Therapeutics announced new preclinical findings for SIL-204, its second-generation siRNA candidate, following the optimization of its extended-release formulation. These latest findings demonstrate that the latest SIL-204-microparticle formulation can inhibit [...]

Merck announced the completion of the acquisition of CN201 from Curon Biopharmaceutical, a novel investigational clinical-stage bispecific antibody for the treatment of B-cell associated diseases. CN201 is currently being investigated [...]

CEL-SCI announced its renewed collaboration with Ergomed Clinical Research for its upcoming FDA confirmatory Registration Study of Multikine in head and neck cancer. Ergomed will provide global comprehensive clinical operations [...]

Gritstone announced interim Phase 2 data from the ongoing Phase 2 study evaluating GRANITE, its individualized neoantigen targeting immunotherapy, in frontline microsatellite stable colorectal cancer, or MSS-CRC. The randomized, controlled [...]

Lexicon Pharmaceuticals will unveil study design details of SONATA-HCM, the company's Phase 3 clinical trial of sotagliflozin as a potential new treatment for adults with hypertrophic cardiomyopathy, at the virtual [...]

Travere Therapeutics announced a voluntary pause of enrollment in the Phase 3 HARMONY Study evaluating pegtibatinase for the treatment of classical homocystinuria HCU . The voluntary enrollment pause enables the [...]